US4783330A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies to activated platelets
Assignee: Tufts Medical Center Inc
•
Filing: 1985-11-08
•
Granted: 1988-11-08
•
Expires: 2005-11-08
Abstract
Abstract An antibody reactive with activated human platelets, and substantially unreactive with resting human platelets, with the azurophilic granules of monocytes, and with granulocytes.
Inventors
- 👤 Bruce E. Furie
- 👤 Barbara C. Furie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 08:18
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1093; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K16/00; C07K16/18; C07K16/28; A61K2123/00; A61K38/00; A61K39/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/808; Y10T; Y10T436/00; Y10T436/24
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
25 words
A monoclonal antibody reactive with activated human platelets, and substantially unreactive with resting human platelets and with the azurophilic granules of monocytes and neutrophilic granulocytes.
Claim 2
Dependent Claim
25 words
A monoclonal antibody reactive with activated human platelets, and substantially unreactive with resting human platelets and with the azurophilic granules of monocytes and neutrophilic granulocytes.
Claim 3
Dependent Claim
38 words
The antibody of claim 1, said antibody being reactive with an antigenic determinant on the surfaces of activated human platelets and not present on the surfaces of resting human platelets or azurophilic granules of monocytes, and neutrophilic granulocytes.
Claim 4
Dependent Claim
25 words
The antibody of claim 1, said antibody recognizing an antigenic determinant on activated human platelets, said antigenic determinant being a protein distinct from glycoprotein IIa.
Claim 5
Dependent Claim
12 words
The antibody of claim 1, said antibody being of the IgG isotype.
Claim 6
Dependent Claim
13 words
The antibody of claim 4, said antibody being of the IgG 1 isotype.
Claim 7
Dependent Claim
24 words
The antibody of claim 2, said antigenic determinant being a glycoprotein on the surface of activated platelets having a molecular weight of about 140,000.
Claim 8
Dependent Claim
18 words
The antibody of claim 1 said antibody recognizing between 10,000 and 17,000 binding sites on activated human platelets.
Claim 9
Dependent Claim
20 words
The antibody of claim 2, said antigenic determinant not being susceptible of stabilization, on activated human platelets, by calcium ions.
Claim 10
Dependent Claim
16 words
The antibody of claim 2, said antigenic determinant not being a constituent of normal human plasma.
Claim 11
Dependent Claim
18 words
The antibody of claim 1, the binding of said antibody to activated platelets being independent of platelet aggregation.
Claim 12
Dependent Claim
7 words
The antibody of claim 1, being labeled.
Claim 13
Dependent Claim
7 words
The antibody of claim 11, being radiolabeled.
Claim 14
Dependent Claim
16 words
The antibody of claim 11, complexed with a paramagnetic ion to form an NMR contrast agent.
Claim 15
Dependent Claim
27 words
A method of detecting activated platelet-containing sites in a human patient comprising administering to said patient the labeled antibody of claim 11 and detecting labeled immune complexes.
Claim 16
Dependent Claim
36 words
A method of assaying a platelet-containing sample for activated platelets comprising contacting said sample with the labeled antibody of claim 11 and measuring labeled immune complexes as a measure of said activated platelets in said sample.
Claim 17
Dependent Claim
12 words
A hybrid cell capable of producing the monoclonal antibody of claim 1.
Claim 18
Dependent Claim
22 words
The antibody of claim 1, being covalently bonded to a compound capable of dissolving an activated platelet-containing clot in a human patient.
Claim 19
Dependent Claim
17 words
The antibody of claim 17 wherein said clot-dissolving compound is tissue plasminogen activator, urokinase, streptokinase, or plasmin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-08 | 1992-05-09 | 1992-11-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-08 | 1996-05-09 | 1996-11-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-08 | 2000-05-09 | 2000-11-08 | $7700.00 | Window Closed / Lapsed |